Cambridge, MA, USA & Rostock, Berlin, GERMANY, 13 September 2019 – CENTOGENE today announced that Arndt Rolfs, Founder and CEO of CENTOGENE has been shortlisted for the EY ‘Entrepreneur of the Year 2019’ for Germany. For the 23rd year, EY selects the best owner-managed companies in Germany. Leaders from 38 companies made it to the final of the competition this year, including Dr. Arndt Rolfs, MD and CEO CENTOGENE.
“I am extremely honored to be a finalist in this year’s Entrepreneur of the Year 2019,” commented Arndt Rolfs, CEO CENTOGENE. “Being a finalist not only underscores my commitment to building a rare disease company devoted to bringing hope and solutions to rare disease patients and their families, but also celebrates the commitment of every CENTOGENE employee in helping to end the diagnostic odyssey that our patients face.”
The winners will be announced on 25 October 2019 in Stuttgart at a festive gala in the Mercedes-Benz Museum, at which EY celebrates its 100th anniversary in Germany. The welcoming speech will be given by the Prime Minister of Baden-Württemberg, Winfried Kretschmann.
The prizes will be awarded in the categories industry, consumer goods / trade, service / IT, digital transformation as well as young companies / start-ups. In addition, EY honors a model family business and entrepreneurial personality for their exceptional social commitment with an honorary award.
About the contest ‘EY Entrepreneur Of The Year’
The ‘Entrepreneur Of The Year’ program was launched in 1986 by EY in the United States. Since then, the competition has established itself in 60 countries and is one of the world's most prestigious business awards. The competition in Germany is supported by well-known companies and the media. These include LGT, the strategic consulting firm for communication Kekst CNC, the Frankfurter Allgemeine Zeitung and the manager Magazin. In addition to honoring successful entrepreneurs, EY also promotes young entrepreneurs with the "EY NextGen Academy" program.
CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients. We are focused on bringing rationality to treatment decisions and accelerating the development of new orphan drugs by using our knowledge of the global rare disease market, including our epidemiological and clinical heterogeneity and our innovative biomarkers. As one of the largest rare disease companies worldwide, CENTOGENE is dedicated to transforming the science of genetic information into solutions and creating hope for our patients with rare diseases and their families.